Undisclosed

Lonza Group

Virtual Booth Global Pharmaceutical Dosage Solutions Company

Switzerland

Contact Supplier

Virtual Booth

AAPS 2020 PHARMSCI 360

Participation Not Confirmed

Update your events

Lonza Partners with Anthos Therapeutics for Thrombosis Treatment

Lead Product(s): Abelacimab

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Anthos Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 11, 2020

Details:

The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

VarmX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

AAPS 2020 PHARMSCI 360

Participation Not Confirmed

Update your events

VarmX Raises €32 Million to Develop Innovative Reversal Agent for the Treatment of Bleeding in Patients on Oral Anticoagulants

Lead Product(s): VMX-COO1

Therapeutic Area: Hematology Product Name: VMX-COO1

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Ysios Capital

Deal Size: $36.6 million Upfront Cash: Undisclosed

Deal Type: Series B Financing July 08, 2020

Details:

Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.

Shanghai Cell Therapy Group

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

AAPS 2020 PHARMSCI 360

Participation Not Confirmed

Update your events

Shanghai Cell Therapy Group Ink Collaboration with USC to Improve Ex Vivo Expansion of Hematopoietic Stem Cells for Clinical Applications

Lead Product(s): Hematopoietic stem cells

Therapeutic Area: Hematology Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Baize Plan Fund

Deal Size: $3.6 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 28, 2020

Details:

Through the project, sponsored by the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.